



Florence, 6th December 2023




National Immunization Plan 2023-2025 and annual updates of immunization schedule

CARLO SIGNORELLI

Professor of Public Health, Vita-Salute San Raffaele University, Milan

President, Italian National Immunization Technical Advisory Group (NITAG)

In collaboration with M. Mastrangelo, E. De Ponti and R. Cuciniello, School of Public Health, Vita-Salute San Raffaele University, Milan



❖ Approved by the State-Regions Conference on August, 8th, 2023



❖ New contents:

- **The immunization schedule can be updated annually**
- Possible introduction of monoclonal antibodies for preventive purposes
- Key role of Departments of Prevention (NHS) for planning and co-ordination of immunization campaigns
- Use of pandemic experience in routine vaccinations (extension of immunization sites)

NITAGs in Italy



- 2017-18 NITAG 1 (R Guerra+21)
- 2018-21 NITAG 2 (V De Micheli+13)
- 2021- NITAG 3 (C Signorelli+29)




Ann Ist Super Sanità 2023 | Vol. 59, No. 1: 26-30
DOI: 10.4415/ANN_23_01_04

The new Italian National Immunization Technical Advisory Group (NITAG) and its commitment to endorse a new efficient National Immunization Plan in COVID-19 times

Andrea Silenzi¹, Andrea Siddu¹, Anna Carole D'Amelio², Sarah Cataldi², Camilla Fasano², Francesco Maraglino¹, Giovanni Rezza¹ and Carlo Signorelli¹

NITAG activity (2021-23)

- 
- Advisory for National Vaccination Plan (2021-23)
 - Advisory for Ministerial acts (Circolari) on immunization strategies (Flu, Monkeypox, COVID-19)
 - Proposal of new National Immunization Schedule (2024)
 - Hearings of stakeholders (Companies, professional associations, boards)

Critical issues of previous National Plan (2017-2019)



● 0-90 ● 90,1-94,9 ● 95-100



Vaccination coverage targets failure (adolescents and adults)



Regional differences in coverage rates




Organizational differences (active call, IT systems)

New (old*) goals of the National Plan

- 1) Maintain polio-free status*
- 2) Elimination of measles and rubella*
- 3) Reduction of HPV-related diseases**
- 4) Vaccination coverage targets*, **using pandemic settings in vaccination campaigns**
- 5) Vaccination of high-risk groups (chronic diseases)**
- 6) Reduce inequalities in vaccinations offer*
- 7) Implement the national digital vaccination registry*
- 8) Improve surveillance of vaccine preventable infections*
- 9) Improve communication on vaccines**
- 10) Promote vaccine education in health care workers*

**Goals also present in previous Plan 2017-2019*



Vaccinations in pharmacies





The role of community pharmacists in vaccination

Position paper

The role of Community Pharmacists in vaccination

Pharmacists can vaccinate in their pharmacies for COVID-19/Influenza in **15** European Countries

■ Vaccination in pharmacies COVID-19/Influenza (15 countries)

■ Pharmacists are able to administer other vaccines and medicines (9 Countries)

Pharmacists are able to administer other vaccines and medicines in **9** European Countries

CAMPAGNA VACCINALE 2023/2024


Regione Lombardia

VACCINO ANTI-COVID19

Somministrazioni al	20/11/2023	=	245.176	
Confronto somministrazioni* al	20/11/2022	=	483.117	Confronto: -237.941

** somministrazioni effettuate con vaccini aggiornati BA4-5 a partire dal 29/09/2022*

CATEGORIE	SOMM.	%
Età ≥ 60	159.366	65%
Soggetto vulnerabile per patologia	29.623	12%
Operatore Sanitario	21.270	9%
Età < 60 anni	15.331	6%
Ospite in struttura sanitaria e socio-sanitaria residenziale e semi-residenziale	14.231	6%
Operatore scolastico	2.363	1%
Convivente di soggetto ad alto rischio	2.226	1%
Altra attività lavorativa a rischio	766	0%
Totale	245.176	100%



CATEGORIA CENTRO	SOMM.	%
FARMACIA	109.976	45%
ASST	71.616	29%
MMG/PLS	40.733	17%
UDO SS	14.660	6%
OSPEDALE	4.673	2%
IRCCS	3.325	1%
ALTRO	193	0%

FASCIA DI ETÀ	SOMM.	%
0-11	449	0%
12-15	217	0%
16-19	338	0%
20-29	3.759	2%
30-39	7.482	3%
40-49	9.663	4%
50-59	18.531	8%
60-69	55.756	23%
70-79	73.408	30%
80-89	59.364	24%
90-99	15.781	6%
100+	428	0%

PROVINCIA	SOMM.
MI	84.936
BG	22.362
BS	35.377
CO	14.186
CR	9.360
LC	8.524
LO	4.826
MN	7.986
MB	19.822
PV	11.578
SO	4.034
VA	22.185



TWO BEST PRACTICES IN VACCINATION OFFER

COVID e Flu vaccines



Pharmacies (1,000/3,000 available)

Alternative to GPs delivery

Regional agreement with Pharmacies

≈25% of total shots in 2023 campaign



Anti-zoster vaccine




Departments of Prevention (NHS)

Active and direct call

A goal for Directors of LHA

>50% coverage in 65 y/o choort


Immunization schedule update



NITAG is updating the **2024 immunization schedule**

- Three working groups:
 - Immunization schedule update
 - Vaccines in high-risk population
 - Vaccines in workers and travellers
- Issues under discussion:
 - anti COVID-19 vaccine in the National schedule
 - Anti-meningococcus B vaccinations in adolescents
 - anti RSV immunization in adults and children

International approaches on anti RSV immunization campaign 2023-24



Haute Autorité de Sante

FRANCE: HAS (French Health authorities) – Reimbursement:

First RSV season: All infants (in accordance with product authorization)



Ministerio de Sanidad

SPAIN: NITAG recommendation (late July) and immunisation schedule of the Spanish Society of Pediatrics:

First RSV season: All infants aged < 6 months

Second RSV season: high-risk infants aged < 24 months



Advisory Committee on Immunization

Practices US: Recommendation ACIP:

First RSV season: All infants aged < 8 months

Second RSV season: Infants (aged 8-19 months) at high-risk of RSV

- Inclusion in Vaccines for Children program (VFC)
- Recommendation American Academy of Pediatrics



Luxembourg NITAG: recommendation and reimbursement for all infants in first RSV season



Austrian NITAG e Ministry of Health: recommendation for all infants in first RSV season

Registered products for RSV prophylaxis in adults



Preventive monoclonal antibodies

- Beyfortus (Nirsevimab) – Sanofi



All infants

- Synagis (Palivizumab) – Abbvie



Infants with gestational age \leq 35w. and aged < 6 months

Vaccines

- Arexvy – GSK



Adults 60+

- Abrysvo – Pfizer



Adults 60+ and pregnant women (for passive immunization newborn 6 months)

Thanks for your attention

